title: Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment.
abstract: Thromboembolic complications constitute an important risk in renal transplant patients, in whom a hypercoagulable state is associated with immunosuppressive treatment, and the presence of hypercoagulability and hypofibrinolysis specifically with cyclosporine. Hypercorticism secondary to steroid treatment has been associated with a thrombophilic state and the presence of a reduced fibrinolytic potential in particular. The aims of this study were to first evaluate the fibrinolytic potential by the venous occlusion (VO) test in 19 renal transplant (RT) patients, and then compare these findings with those obtained in similar groups of normal subjects and patients with Cushing's disease. The following tests were carried out before and after the VO test: euglobulin lysis time and t-PA and PAI-1 activities and antigen. Compared with normal controls, RT and Cushing's patients both showed a similar significant increase in PAI-1 activity and concentration. The VO test revealed a similar impairment in fibrinolytic potential in both the RT and Cushing groups. High and pathological PAI-1 levels before and after the VO test were consistent with a defective fibrinolytic potential due to the inhibitory effect of PAI-1 on plasminogen activation. A hypofibrinolytic state was found in 68.4% of RT patients. Our results suggest that an imbalance in the fibrinolytic system is a typical feature of RT patients one year after transplantation. Steroids appear to be the immunosuppressive drug mainly involved in determining thromboembolic risk after renal transplantation.
authors.affiliation: Institute of Medical Semeiotics, University of Padua Medical School, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: Patrassi
authors.forename: M T
authors.initials: MT
authors.lastname: Sartori
authors.forename: P
authors.initials: P
authors.lastname: Rigotti
authors.forename: D
authors.initials: D
authors.lastname: Di Landro
authors.forename: P
authors.initials: P
authors.lastname: Theodoridis
authors.forename: M
authors.initials: M
authors.lastname: Fioretti
authors.forename: M
authors.initials: M
authors.lastname: Capalbo
authors.forename: G
authors.initials: G
authors.lastname: Saggiorato
authors.forename: G
authors.initials: G
authors.lastname: Boeri
authors.forename: A
authors.initials: A
authors.lastname: Girolami
mesh_terms: D000328:Adult; D003480:Cushing Syndrome / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000097:blood*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011239:Prednisolone / Q000009:adverse effects; D013923:Thromboembolism / Q000139:chemically induced / Q000209:etiology; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D005343:Fibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; D016572:Cyclosporine; D011239:Prednisolone; D010959:Tissue Plasminogen Activator